ArticleAdvanced biomedical research2025
Duplication of the Rabies Virus Glycoprotein Enhances the Virus Propagation Rate and Immunogenicity.
Article in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhanced immunogenicity of the rabies virus glycoprotein fused to a dendritic cell-targeting peptide.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The most effective approach to control and prevent rabies is by proper pre- and post-exposure immunization. Glycoprotein (G) is a structural protein of the rabies virus that plays a crucial function in host protection against the virus. This study assessed the effects of integrating an extra copy of the glycoprotein gene into the rabies virus genome using reverse genetics on the immunogenicity and titer of the recombinant virus. Materials and Methods: The expression of the recombinant viral glycoprotein was compared to the PV strain using qRT-PCR and western blot techniques. The virus titers were studied using a fluorescent antibody test (FAT). The inactivated recombinant virus was administered to BALB/c mice as a vaccine, and the immunogenicity was assessed using the rapid fluorescent focus inhibition test (RFFIT). Results: Glycoprotein overexpression was observed using qRT-PCR (2.47-fold increase) and confirmed by western blot analysis (3.4-fold increase). The double G virus showed significantly higher virus titers than the PV strain. The immunogenicity of the double G virus was also considerably increased. The VNA titers induced by the double G virus were approximately two and three times higher at 14 and 21 days post-inoculation, respectively. Conclusions: Based on our findings, the PV strain's G gene duplication showed greater viral titers, better VNA induction, and higher G expression levels. Both the development of rabies vaccines and the investigation of various cellular processes involved in the virus's life cycle may be advanced by characterizing the recombinant double G strain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.